178 related articles for article (PubMed ID: 29970101)
1. Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer.
Liu Z; Poiret T; Meng Q; Rao M; von Landenberg A; Schoutrop E; Valentini D; Dodoo E; Peredo-Harvey I; Maeurer M
J Transl Med; 2018 Jul; 16(1):182. PubMed ID: 29970101
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
3. CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors.
Meng Q; Valentini D; Rao M; Dodoo E; Maeurer M
Sci Rep; 2018 Nov; 8(1):17079. PubMed ID: 30459443
[TBL] [Abstract][Full Text] [Related]
4. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
[TBL] [Abstract][Full Text] [Related]
5. Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy.
Nagu T; Aboud S; Rao M; Matee M; Axelsson R; Valentini D; Mugusi F; Zumla A; Maeurer M
Int J Infect Dis; 2017 Mar; 56():136-139. PubMed ID: 28193504
[TBL] [Abstract][Full Text] [Related]
6. Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.
Theeten H; Mathei C; Peeters K; Ogunjimi B; Goossens H; Ieven M; Van Damme P; Cools N
Viral Immunol; 2016 Apr; 29(3):169-75. PubMed ID: 27002465
[TBL] [Abstract][Full Text] [Related]
7. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
8. Expression of tegument protein pp65 of human cytomegalovirus (CMV) and its application to the analysis of viral-specific cellular immunity in CMV-infected individuals.
Tanaka N; Kimura H; Hoshino Y; Nishikawa K; Kojima S; Nishiyama Y; Morishima T
Arch Virol; 2002 Dec; 147(12):2405-17. PubMed ID: 12491106
[TBL] [Abstract][Full Text] [Related]
9. Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.
Dungan L; Dunne J; Savio M; Kalaszi M; McElheron M; Lynagh Y; O'Driscoll K; Roche C; Qureshi A; Crowley B; Conlon N; Kearney H
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200217. PubMed ID: 38547427
[TBL] [Abstract][Full Text] [Related]
10. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
11. Altered humoral immunity against cytomegalovirus and Epstein-Barr virus without detectable virus antigens and virus-DNA in the glomeruli of patients with IGA nephropathy in remission phase.
Nagy J; Haikin H; Sarov B; Háber A; Kun L; Sarov I
Acta Microbiol Immunol Hung; 1995; 42(2):179-87. PubMed ID: 7551711
[TBL] [Abstract][Full Text] [Related]
12. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
[TBL] [Abstract][Full Text] [Related]
13. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
14. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.
Wakefield A; Pignata A; Ghazi A; Ashoori A; Hegde M; Landi D; Gray T; Scheurer ME; Chintagumpala M; Adesina A; Gottschalk S; Hicks J; Powell SZ; Ahmed N
J Neurooncol; 2015 Nov; 125(2):307-15. PubMed ID: 26341370
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
18. The detection of CMV pp65 and IE1 in glioblastoma multiforme.
Lucas KG; Bao L; Bruggeman R; Dunham K; Specht C
J Neurooncol; 2011 Jun; 103(2):231-8. PubMed ID: 20820869
[TBL] [Abstract][Full Text] [Related]
19. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.
Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M
Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus- and Epstein-Barr Virus-Induced T-Cell Expansions in Young Children Do Not Impair Naive T-cell Populations or Vaccination Responses: The Generation R Study.
van den Heuvel D; Jansen MA; Dik WA; Bouallouch-Charif H; Zhao D; van Kester KA; Smits-te Nijenhuis MA; Kolijn-Couwenberg MJ; Jaddoe VW; Arens R; van Dongen JJ; Moll HA; van Zelm MC
J Infect Dis; 2016 Jan; 213(2):233-42. PubMed ID: 26142434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
